Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Multiple Sclerosis

    New Mexico

    Search
    Multiple Sclerosis
    New Mexico
    Show Map
    Map View
    New Mexico
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      17 Multiple Sclerosis Trials near New Mexico

      Power is an online platform that helps thousands of Multiple Sclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication
      Active on Power

      Frexalimab for Multiple Sclerosis

      Albuquerque, New Mexico
      The study is evaluating the efficacy and safety of Frexalimab in patients with non-relapsing, secondary progressive MS. The primary objective is to determine whether Frexalimab can delay disability progression compared to placebo.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Infection Risk, Psychiatric Disturbance, Others
      Must Not Be Taking:Antithrombotics

      858 Participants Needed

      Active on Power

      Frexalimab for Multiple Sclerosis

      Albuquerque, New Mexico
      The study is evaluating whether Frexalimab performs better than the existing MS medication, Teriflunomide, at reducing the number of relapses in patients with relapsing forms of multiple sclerosis.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, Infection Risk, Psychiatric Disturbance, Others
      Must Not Be Taking:Antithrombotics

      1400 Participants Needed

      Remibrutinib vs Teriflunomide for Multiple Sclerosis

      El Paso, Texas
      This trial compares two medications, remibrutinib and teriflunomide, for treating patients with relapsing multiple sclerosis. These patients have repeated episodes of symptoms and need effective treatments. The medications work by controlling the immune system to prevent it from causing damage to the nervous system. Teriflunomide is an approved medication for adults with relapsing multiple sclerosis.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, CNS Disease, Substance Abuse, Others
      Must Not Be Taking:Leflunomide, Methotrexate, CYP3A4 Inhibitors

      800 Participants Needed

      ABP 692 vs Ocrelizumab for Multiple Sclerosis

      Albuquerque, New Mexico
      The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Primary Progressive MS, Secondary Progressive MS, Others
      Must Not Be Taking:Systemic Corticosteroids, Immunosuppressants

      444 Participants Needed

      Tolebrutinib for Multiple Sclerosis

      Albuquerque, New Mexico
      This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 \[EFC16033\], GEMINI 2 \[EFC16034\], HERCULES \[EFC16645\], or PERSEUS \[EFC16035\]). SUBSTUDY: ToleDYNAMIC substudy
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Infections, Alcohol Abuse, Liver Disease, Others
      Must Not Be Taking:CYP3A Inducers, CYP2C8 Inhibitors

      2500 Participants Needed

      Fenebrutinib for Relapsing Multiple Sclerosis

      Albuquerque, New Mexico
      A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. At the end of the DBT phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension phase of the study.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Primary Progressive MS, Active Infection, Cancer, Neurological Disorders, Others
      Must Not Be Taking:Systemic Corticosteroids, Immunosuppressants

      746 Participants Needed

      Tolebrutinib for Primary Progressive Multiple Sclerosis

      Albuquerque, New Mexico
      Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis, Tuberculosis, Others
      Must Not Be Taking:Anticoagulants, Antiplatelets, CYP3A Inducers

      767 Participants Needed

      Ublituximab for Multiple Sclerosis

      Albuquerque, New Mexico
      The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Pregnancy, Malignancy, Others
      Must Be Taking:Ublituximab

      1100 Participants Needed

      Ozanimod vs Fingolimod for Multiple Sclerosis

      El Paso, Texas
      The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Progressive MS, Immune Diseases, Cardiovascular, Others

      194 Participants Needed

      Ofatumumab for Early Relapsing-Remitting Multiple Sclerosis

      Albuquerque, New Mexico
      This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if there are similarities between the groups after the patients with MS undergo treatment with ofatumumab.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 4
      Age:18 - 35

      Key Eligibility Criteria

      Disqualifiers:Neuromyelitis Optica, Active Infections, Others
      Must Not Be Taking:Experimental Drugs, Chemotherapy

      180 Participants Needed

      mRNA-1195 for Multiple Sclerosis

      El Paso, Texas
      The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Fever, Unstable Condition, Myocarditis, Others
      Must Not Be Taking:Systemic Immunosuppressants

      180 Participants Needed

      PIPE-307 for Multiple Sclerosis

      Albuquerque, New Mexico
      This trial is testing a new drug called PIPE-307 to see if it can help people with relapsing-remitting multiple sclerosis. The drug likely works by calming the immune system to prevent nerve damage. The study will compare two different doses of PIPE-307 over several months.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Optic Neuritis, Severe Myopia, Others
      Must Be Taking:Immunomodulatory DMT

      168 Participants Needed

      BIIB091 for Relapsing Multiple Sclerosis

      Albuquerque, New Mexico
      In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part study. In Part 1, one set of participants will take either BIIB091 or diroximel fumarate (DRF). In Part 2, a different set of participants will take either a combination of BIIB091 and DRF or DRF alone. The goal of the study is to learn more about the safety of BIIB091 and to compare the effects of the study drug when taken alone or together with DRF. The main question researchers are trying to answer are: * How many participants have new or worsening medical problems (adverse events) after taking BIIB091 or DRF? * How many new areas of inflammation occur in the brain after treatment with BIIB091 and DRF? Researchers will use magnetic resonance imaging (MRI) scans to compare images of the brain before and after treatment. They will also explore the effect of BIIB091 and DRF on the heart using electrocardiograms (ECGs). The study will be done as follows: * After screening, participants who joined Part 1 will be randomly assigned to receive either a high or low dose of BIIB091, or the standard dose of DRF. * The results of Part 1 will be used to choose the best dose of BIIB091 to use in Part 2. * Participants who join Part 2 will be randomly assigned to receive either a standard dose of DRF, a combo of BIIB091 and the standard dose of DRF, or a combo of BIIB91 with a low dose of DRF. * Neither the researchers nor the participants will know which drug or dose the participants will receive in either part of the study. * The treatment period will last 48 weeks in each part of the study. Participants will take the drugs by mouth 2 times a day. * Each part will also have a follow-up safety period that lasts up to 2 weeks. * In total, participants in each part will have 20 study visits, or more if they have a relapse. The total study duration for participants will be up to 54 weeks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:PPMS, Recent MS Relapse, HIV, Others
      Must Not Be Taking:Fumarates, BTK Inhibitors

      275 Participants Needed

      LY3541860 for Multiple Sclerosis

      El Paso, Texas
      The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Primary Progressive MS, CNS Disease, Others

      200 Participants Needed

      Ofatumumab for Multiple Sclerosis

      Albuquerque, New Mexico
      Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      562 Participants Needed

      IMU-838 for Progressive Multiple Sclerosis

      Albuquerque, New Mexico
      This trial is testing a new medication called IMU-838 to help adults with Progressive Multiple Sclerosis. The medication aims to reduce inflammation and slow down the worsening of the disease. The study will check if the medication is safe and effective over a long period.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      450 Participants Needed

      RE104 for Adjustment Disorder

      Albuquerque, New Mexico
      The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Bipolar, Schizophrenia, Psychotic, Others
      Must Be Taking:Antidepressants

      100 Participants Needed

      Why Other Patients Applied

      "I have been losing mobility in the past 3 years very rapidly. I have tried physical therapy, but it didn't really show results. I'll admit that I am not very self-motivated, so I can use some structure. I use to be extremely active and now I am like a wet rag. So I am hoping that participating in a research trial will be of help to me."

      AK
      Multiple Sclerosis PatientAge: 75

      "I've been taking Kesimpta for a couple years now and seem to be having more flare ups. I'm only 43. I have 5 kids and feel like I'm missing my life. Sleeping my life away. I'm ready to try ANYTHING for a chance at living life again."

      XJ
      Multiple Sclerosis PatientAge: 43

      "I've tried 2 MS drugs but I am getting worse. I am having trouble walking long distances or for more than 30 minutes. I need to find a new medication. My doctor and I discussed some of the options in trials and I'm ready to dive in to learn more."

      OL
      Multiple Sclerosis PatientAge: 57

      "I've been battling multiple sclerosis for 28 years. I've tried three medications. I keep my dosing stable, but I'm just tired of managing. I want to take control of my situation."

      KE
      Multiple Sclerosis PatientAge: 43

      "I am 42 yrs old with 2 little kids, work as a nurse, tried several drugs, most made me feel awful. I want my quality of life. I don’t want to have to take something daily/monthly. I don’t like the side effects of many drugs. I'm excited to be considered as a candidate for one of these trials."

      KT
      Multiple Sclerosis PatientAge: 44
      Match to a Multiple Sclerosis Trial

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Multiple Sclerosis clinical trials in New Mexico pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Multiple Sclerosis clinical trials in New Mexico work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Multiple Sclerosis trials in New Mexico 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New Mexico for Multiple Sclerosis is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New Mexico several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Multiple Sclerosis medical study in New Mexico?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Multiple Sclerosis clinical trials in New Mexico?

      Most recently, we added RE104 for Adjustment Disorder, mRNA-1195 for Multiple Sclerosis and Ozanimod vs Fingolimod for Multiple Sclerosis to the Power online platform.

      Can MS go into remission?

      Yes. In relapsing-remitting MS the immune attack can quiet down for weeks, months, or even years, letting symptoms ease or disappear; neurologists try to extend these quiet spells—called remission or “no evidence of disease activity” (NEDA)—with early use of disease-modifying drugs, healthy habits, and regular MRI checks. Remission isn’t a cure because slow nerve damage can still smolder, and it is uncommon in secondary- or primary-progressive MS, so sticking with treatment and follow-up appointments remains vital even when you feel well.

      What is the most common cause of death in MS patients?

      Death certificates show that the commonest “underlying” cause of death in people with MS is the disease itself (ICD-10 G35), accounting for roughly half of all deaths; this label usually stands for advanced disability complicated by infections and breathing problems. Cardiovascular disease and cancer trail well behind (each about one-tenth to one-fifth of deaths), so focusing on preventing aspiration, treating infections quickly, staying mobile, and managing heart-health risks offers the biggest leverage for living longer with MS.

      What not to do if you have MS?

      Think of “don’ts” in three buckets: 1) anything that drives inflammation (smoking, heavy drinking, high-salt or highly processed, high-saturated-fat foods); 2) anything that lets the body decondition or overheat (long periods of inactivity, extreme heat without cooling strategies); and 3) anything that interferes with treatment safety (skipping or delaying prescribed medicines, starting high-dose supplements or live vaccines, or stopping disease-modifying therapy without your neurologist’s okay). Steering clear of these pitfalls, while staying active, eating mostly whole foods, and working closely with your MS team, gives the best chance of slowing attacks and disability.

      What is the new test for MS?

      Doctors now have a spinal-fluid test called the “kappa free light-chain (KFLC) index,” which measures tiny antibody pieces instead of looking for oligoclonal bands. In several large studies it identified multiple sclerosis with about 90–95 % sensitivity and 85–90 % specificity, is run on an automated machine (so it’s faster, cheaper, and less subjective), and many centers are beginning to add it to the standard work-up, although it still requires a lumbar puncture and currently complements rather than fully replaces oligoclonal-band testing.

      Is MS a disability?

      Multiple sclerosis is recognized by disability laws in the U.S., U.K., Canada and many other countries, but you are considered “disabled” only if your specific symptoms—such as fatigue, vision loss, or mobility problems—limit everyday tasks or steady work despite treatment. Because MS progression varies widely (some stay mild for decades while roughly one-third need a cane within 15 years), keep detailed medical records and talk with your neurologist, employer, or a benefits adviser early to document limitations, request job accommodations, or file for disability support if needed.

      How many brain lesions are normal with MS?

      There isn’t a “normal” or required lesion count for multiple sclerosis: some people have none on the first MRI, others show a handful, and studies put the typical range at roughly 5–15 lesions. What matters more to doctors is where the spots are and whether new ones appear over time—four or more lesions, especially in key areas like around the ventricles, can raise concern for future disability, but prognosis depends on the pattern and evolution rather than any single number.

      Has anyone reversed MS?

      So far no treatment has reliably “turned MS off” for everyone, but limited reversal of disability can occur. Many patients regain some or all lost function after a relapse, and small clinical trials of autologous stem-cell transplantation show that about 50-70 % of carefully selected, highly active cases improve their disability scores for several years, though the procedure carries notable risks and is not yet routine care. Current disease-modifying drugs aim to prevent new damage, and research into remyelination medicines is underway, but a guaranteed, widely available way to reverse MS does not yet exist.

      Are MS cases on the rise?

      Yes, the head-count of people living with multiple sclerosis is climbing worldwide—up roughly one-third since 1990—largely because people are being diagnosed earlier and living longer with the disease. New cases per year (incidence) have risen only modestly and unevenly, suggesting that improved detection and better treatments, rather than an explosive growth in risk, account for most of the increase, though lifestyle factors such as low vitamin D, obesity, smoking and EBV infection may also play a smaller role.

      Does MS run in families?

      MS can cluster in families, but it is not passed down in a simple all-or-nothing way: the lifetime chance is about 1 in 300 for anyone, rises to roughly 1 in 30 (≈2–3 %) if you have a parent, child, or sibling with MS, and even identical twins match only about 1 in 4 times—proof that genes are only part of the story. Because most relatives never develop the disease, routine genetic testing isn’t recommended; instead, general health steps that may lower risk (adequate vitamin D, avoiding smoking, healthy weight) are sensible for everyone.

      What is the progressive treatment for MS?

      Treatment for progressive MS has two parts. First, disease-modifying drugs such as ocrelizumab (for primary-progressive) and siponimod or, in some cases, cladribine/rituximab (for active secondary-progressive) can slow further disability when started early under an MS specialist’s care. Second, an ongoing personalised plan—physiotherapy and exercise, medicines for spasticity, pain, bladder or fatigue, plus good sleep, diet, vaccination and prompt treatment of infections—helps control day-to-day symptoms and prevents complications, with regular reviews to adjust both pieces as the condition evolves.

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      15 Autism Trials near Chicago, IL

      Top Clinical Trials near Cranberry Township, PA

      Top Photodynamic Therapy Clinical Trials

      Top Prostate Cancer Clinical Trials near Glendale, AZ

      175 Clinical Trials near Big Rapids, MI

      Top Clinical Trials near Homestead, FL

      Top Diabetic Retinopathy Clinical Trials

      Top Clinical Trials near Fort Deterick, MD

      Top Huntington Disease Clinical Trials

      Top Mycosis Fungoides Clinical Trials

      Top Clinical Trials near Augusta, GA

      231 Clinical Trials near Benzonia, MI

      By Trial

      Mediterranean Diet for Psoriasis

      Combination Therapy for Anxiety Disorders

      Raludotatug Deruxtecan for Cancer

      Combination Chemotherapy + Acalabrutinib for Mantle Cell Lymphoma

      Lumbar Medial Branch Blocks for Facet Joint Pain

      Produce Prescription for Childhood Obesity

      FIRST Psychotherapy for Youth Mental Health Issues

      CPSD for Gastrostomy

      Lenalidomide + Dexamethasone +/- Daratumumab for Multiple Myeloma

      PET Scan with DPA-714 for Parkinson's Disease

      Anti-EGFR Therapy for Colorectal Cancer

      Imaging Agent + Ultrasound for Prostate Cancer